Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 9, 770–771 (1 November 2009) | doi:10.1038/nrc2754
Therapy: Swings and roundabouts
Abstract
Children with neurofibromatosis type 1 are heterozygous for NF1 and have a substantially increased risk of developing an aggressive myeloproliferative disorder (MPD): juvenile myelomonocytic leukaemia (JMML). Using mouse models, Jennifer Lauchle, Kevin Shannon and colleagues have identified the stages of this disease that might be amenable to treatment with drugs that target the RAF–MEK–ERK signalling pathway.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
